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1. Abstract 1 
The clinical utilization of recombinant human bone morphogenetic protein 2 (rhBMP-2) 2 
delivery systems for bone regeneration has been associated with very severe side effects, which 3 
are due to the non-controlled and non-targeted delivery of the growth factor from its collagen 4 
sponge carrier post-implantation which necessitates supraphysiological doses. However, 5 
rhBMP-2 presents outstanding regenerative properties and thus there is an unmet need for a 6 
biocompatible, fully resorbable delivery system for the controlled, targeted release of this 7 
protein. With this in mind, the purpose of this work was to design and develop a delivery system 8 
to release low rhBMP-2 doses from a collagen‐hydroxyapatite (CHA) scaffold which had 9 
previously been optimized for bone regeneration and recently demonstrated significant healing 10 
in vivo. In order to enhance the potential for clinical translation by minimizing the design 11 
complexity and thus upscaling and regulatory hurdles of the device, a microparticle and 12 
chemical functionalization-free approach was chosen to fulfil this aim. RhBMP-2 was 13 
combined with a CHA scaffold using a lyophilization fabrication process to produce a highly 14 
porous CHA scaffold supporting the controlled release of the protein over the course of 21 days 15 
while maintaining in vitro bioactivity as demonstrated by enhanced alkaline phosphatase 16 
activity and calcium production by preosteoblasts cultured on the scaffold. When implanted in 17 
vivo, these materials demonstrated increased levels of healing of critical-sized rat calvarial 18 
defects 8 weeks post-implantation compared to an empty defect and unloaded CHA scaffold, 19 
without eliciting bone anomalies or adjacent bone resorption. These results demonstrate that it 20 
is possible to achieve bone regeneration using 30 times less rhBMP-2 than INFUSE®, the 21 
current clinical gold standard; thus, this work represents the first step of the development of a 22 
rhBMP-2 eluting material with immense clinical potential.  23 
 24 
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2. Keywords 1 
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3. Introduction 4 
The FDA approval for the utilization of recombinant human bone morphogenetic protein 2 5 
(rhBMP-2) in 2002, represented a major milestone in the field of bone tissue regeneration[1]. 6 
Based on this approval, Medtronic commercialized INFUSE®, a collagen based sponge that is 7 
soak-loaded in a solution of several milligrams of rhBMP-2 prior to implantation, for spinal 8 
fusion procedures in skeletally mature patients with degenerative disc disease. Driven by this 9 
product, in 2010, Medtronic became the leader in the field with 44 % of the $1.9 billion bone 10 
graft market. However, an increasing body of evidence has demonstrated INFUSE® to be 11 
associated with numerous complications related to off-label use such as heterotopic 12 
ossification, osteolysis, increased neurological deficits, or cancer; all these serious side effects 13 
have been linked to the uncontrolled and offsite release of rhBMP-2[2-4]. 14 
RhBMP-2 is a primary growth factor (GF) for bone tissue regeneration, and it is involved in 15 
the commitment of multipotent stem cells towards the osteogenic lineage, eliciting an 16 
outstanding pro-osteogenic effect[5]. In this regard, there has been significant effort in the 17 
development of a biocompatible substrate that can support the spatiotemporally controlled 18 
release of rhBMP-2, in order to overcome the current therapeutic limitations associated with 19 
INFUSE®. Such materials while providing a solution to current publicized BMP risks may 20 
also facilitate better bone regeneration for those in need. Indeed, a wide array of substrates have 21 
been proposed, from inorganic materials, to hydrogels and porous organic composites to name 22 
a few, showing some encouraging results[6-11]. However, despite these promising outcomes, 23 
it is likely that for most of these materials the path to clinical utilization will take several years, 24 
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as they imply complex designs or the usage of novel polymers or their combinations, which 1 
will probably incur time consuming upscaling and regulatory hurdles[12]. 2 
The tissue engineering research laboratory at the Royal College of Surgeons in Ireland (RCSI) 3 
has recently patented and licensed HydroxyColl®, a biomimetic crosslinked collagen‐4 
hydroxyapatite (CHA) porous scaffold which is biocompatible, bioresorbable, osteoconductive 5 
and osteoinductive[13-16]. This biomaterial, which has shown evidence of healing critical-size 6 
defects on a rabbit radius and rat calvaria, is undergoing regulatory examinations for FDA and 7 
CE mark approval and is expected to be utilized in clinical trials by the end of 2015. Due to the 8 
regenerative properties of this scaffold, the present work focused on investigating the potential 9 
of utilizing this CHA scaffold for the sustained delivery of rhBMP-2, further improving its 10 
regenerative potential using a method which could be applied to other scaffolds. 11 
 12 
In order to facilitate delivery of rhBMP-2 from these CHA scaffolds, we aimed to see if it was 13 
possible to adopt a carrier-free approach, without the utilization of pre- or post-fabrication 14 
scaffold functionalization processes previously adopted[17-19]. As such, we evaluated the 15 
possibility of controlling the dosage and the release of the bioactive GF by incorporating it 16 
within the structure of the scaffold, during its lyophilization fabrication process. This approach 17 
was investigated based on two particular features of rhBMP-2: i) its high stability in acidic 18 
environments[20, 21], which are used in the fabrication of the scaffolds and ii) its documented 19 
non covalent bonding with hydroxyapatite crystals, which are a component of the CHA 20 
scaffolds, via the -OH, -NH2, and -COO
− functional groups[22, 23]. These unique 21 
characteristics were hypothesized to facilitate sustained, long term delivery of low doses of the 22 
protein post implantation thereby overcoming the risks associated with INFUSE®. 23 
Initially, this study explored whether it was possible to directly incorporate rhBMP-2 into the 24 
scaffold using the proposed lyophilization method and subsequently how the incorporation of 25 
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the GF into CHA scaffolds affected their architecture, the release profile of the GF from 1 
scaffolds as well as the bioactivity of the protein were studied. The regenerative capacity of 2 
this rhBMP-2-loaded scaffold to heal bony defects was subsequently investigated in vivo using 3 
a critically sized rat calvarial defect model over an 8 week period and the results were compared 4 
to unloaded CHA scaffolds and empty defect controls. 5 
4. Materials and Methods 6 
4.1. Scaffold fabrication 7 
Collagen-hydroxyapatite (CHA) scaffolds were fabricated using a patented process developed 8 
within our laboratory[16] with the omission of the chemical crosslinking step so as to avoid 9 
loss of protein in solution prior to use in vitro and in vivo. Briefly, 1.8 g of micro-fibrillar 10 
bovine tendon collagen was added to 320 mL of 0.5 M acetic acid solution. This suspension 11 
was blended at 15,000 rpm for 90 min using an overhead blender in a reaction vessel which 12 
was kept at 4 °C using a circulation system to prevent heat denaturation of the collagen. 13 
Aliquots of 10 mL of a solution of 3.6 g of HA in 40 mL of 0.5 M acetic acid solution were 14 
added every 60 min followed by additional blending. The slurry was degassed under vacuum 15 
to remove air bubbles which may lead to uncontrolled porosity. In order to incorporate rhBMP-16 
2 into the scaffold, rhBMP-2 (R&D Systems UK) was gently mixed with the CHA slurry after 17 
the degassing step at a final dose of 12 µg rhBMP–2/mL slurry and 9 mL of slurry was used to 18 
produce a scaffold in a 4.5 × 4.5 cm stainless steel tray (50 ng/cm2 of scaffold or 1.5 µg per 19 
scaffold). The in vitro BMP-2 release of a series of CHA scaffolds incorporating different 20 
amounts of rhBMP-2 was analyzed prior to this study. Among them, the scaffold fabricated 21 
with a slurry containing 12 µg/mL rhBMP-2 was selected with a release rate of 50–100 ng/mL 22 
of rhBMP-2 per timepoint since this concentration of rhBMP-2 elicits an optimal response on 23 
the osteoblast cell line used for in vitro characterization. 24 
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The mixtures were lyophilized at -10 °C using a constant cooling freeze-drying protocol. 1 
Subsequently, the scaffolds were sterilized under UV light for 4 h (λ=254 nm). 2 
4.2. Assessment of rhBMP-2 release from scaffolds 3 
4.2.1 Scaffold characterization 4 
The morphological characterization of the scaffolds was carried out by Scanning Electron 5 
Microscopy (SEM) using a Zeiss Supra Variable Pressure Field Emission Scanning Electron 6 
Microscope. Scaffolds were cut (6 mm diameter and 4 mm height) and mounted onto metallic 7 
studs with the help of carbon-based glue and sputtered with gold and SEM images were 8 
captured at a voltage of 5 kV using secondary electron mode, taken at a working distance 9 
between 12 and 18mm.  10 
4.2.2 In vitro bioactivity assays 11 
To examine rhBMP-2 release profile, 6 mm diameter scaffolds were placed in 2 mL of PBS in 12 
a shaking water bath at 37 ºC. At given time-points up to 21 days, release media were removed, 13 
replaced by fresh PBS and the protein concentration was determined by ELISA using a rhBMP-14 
2 ELISA kit (R&D Systems UK) according to the manufacturer’s instructions. At later 15 
timepoints the scaffolds begins to degrade and lose structural integrity. Prior to this point the 16 
concentration of protein delivered from the scaffold was between 50 and 100 ng/mL per time 17 
point considered optimal for eliciting a pro-osteogenic effect on osteoblast cells[24]. 18 
The bioactivity of the scaffolds loaded with rhBMP-2 was studied using MC3T3-E1 cells, a 19 
murine pre-osteoblast cell line, in order to study the effects of the scaffolds on osteoblast 20 
proliferation and differentiation in vitro since they exhibit similar properties as osteoprogenitor 21 
cell lines [25] and form calcified bone tissue[26]. Cells were cultured in α-MEM supplemented 22 
with 10% fetal bovine serum (FBS), 1% L-glutamine and 2% penicillin/streptomycin, the 23 
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medium was changed every 3 days. Cells were trypsinized (trypsin–EDTA 0.25%), seeded on 1 
6 well plates at a density of 30,000 cells per well and cultured for 24 h in standard growth 2 
media followed by growth media supplemented with ascorbic acid 2-P 50 µM, dexamethasone 3 
100 nM, β-glycerophosphate 10 mM, FBS 10%, 100 U/mL penicillin and 100 µg/mL 4 
streptomycin under standard conditions (37 °C, 5% CO2).  5 
To analyze the influence of rhBMP-2 eluting scaffolds on cell proliferation, DNA was 6 
quantified after 3 and 7 days of culture. At those timepoints, the cell seeded scaffolds were 7 
homogenized in lysis buffer using a rotor–stator homogenizer (Omni International, Germany), 8 
the cell/scaffold suspension was centrifuged (2500 ×g, 10 min, 4 ºC) and the supernatant was 9 
collected and used for dsDNA analysis using the PicoGreen assay (Quanti-iT TM PicoGreen 10 
dsDNA Molecular Probes, OR, USA) according to the manufacturer’s instructions. 11 
The osteogenic potential of MC3T3-E1 cells on the rhBMP-2 eluting scaffolds was assessed 12 
and compared to unloaded (rhBMP-2-free) CHA scaffolds by quantifying the activity of ALP, 13 
a widely exploited early biochemical marker for osteogenic activity 3 and 7 days post-14 
seeding[27]. At the endpoint of the study constructs containing MC3T3-E1 cells were washed 15 
in PBS, lysed according to the manufacturer’s protocol in lysis buffer (SensoLyte pNPP 16 
Alkaline Phosphatase Assay Kit) and incubated at 4 ºC. The supernatant was collected for 17 
quantification of ALP. This method utilizes p-nitrophenylphosphate (pNPP) that is hydrolyzed 18 
by ALP to produce a yellow product. The amount of colored product is proportional to the 19 
amount of enzyme in the reaction mixture.  20 
Quantification of calcium deposition within osteogenesis experiments was performed using the 21 
Calcium Liquicolor kit (Stanbio Laboratories). The scaffolds were removed from culture at day 22 
14 and solubilized in 1 mL of 0.2 M HCl overnight at 4ºC on a shaker and the amount of 23 
calcium was determined according to the manufacturer’s protocol. 24 
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4.3. Assessment of the effects of rhBMP-2 release on bone repair 1 
4.3.1 In vivo procedure 2 
Once the bioactivity of the eluting scaffolds was confirmed in vitro, scaffolds with a diameter 3 
of 7 mm (2 µg rhBMP-2 per scaffold) were implanted in 7 mm critical-sized calvarial defects 4 
[28] generated on adult male Wistar rats (n=8, mean weight 375 g, range 360–395 g) (Harlan, 5 
UK) in order to assess the ability of BMP-2 CHA scaffolds to promote bone regeneration. For 6 
comparative purposes, a second group of animals (n=8) received unloaded CHA scaffolds, 7 
while a third group (n=8) received no scaffold and these empty defects served as a negative 8 
control. 9 
In vivo analysis was conducted in accordance with protocols approved by the Research Ethics 10 
Committee of the Royal College of Surgeons in Ireland and an animal license was granted by 11 
the Irish Government Department of Health (Ref. B100/4416). General anesthesia, the creation 12 
of the 7-mm-diameter critical-size cranial defect, the placement of the composite materials in 13 
the defect site, and postoperative animal care were performed using established methods[28]. 14 
The generation of a 7-mm-diameter critical-size calvarial defect, the implantation of the 15 
scaffolds in the defect site and the procedures for postoperative animal care were performed 16 
using methods established in the Tissue Engineering Research Group (TERG) of the Royal 17 
College of Surgeons in Ireland (RCSI)[28, 29]. Anesthesia was induced with intraperitoneal 18 
medetomidine hydrochloride 0.3 mg/kg and ketamine hydrochloride 70 mg/kg and maintained 19 
with inhalational isoflurane (0.5–2%) and oxygen. Pre-operative analgesia and antibiotic 20 
prophylaxis were administered before the skin over the head was shaved and the area painted 21 
with 7.5% povidone-iodine antiseptic surgical scrub prior to draping. An ~3mm longitudinal 22 
incision was made over the cranial vault, with dissection down to the  left parietal bone before 23 
a trephine bur drill was used to create a 7 mm circular transosseous defect. Drilling was 24 
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performed under constant irrigation with 0.9% NaCl saline solution and the dura was identified 1 
to confirm that a transosseous defect had been created. Scaffolds were implanted into the 2 
defect, after which the periosteum and superficial connective tissue were closed in layers with 3 
3-0 absorbable monofilament sutures (Monocryl™) and finally a topical skin adhesive (n-butyl 4 
cyanoacrylate). Post-operatively, rats were given a subcutaneous injection of the reversal agent 5 
atipamezole 1.2 mg/kg and placed in an incubator at 27º C until fully recovered. Animals were 6 
housed (2 per cage) in the Biomedical Research Facility at the RCSI with ad libitum access to 7 
water, food and environmental enrichment.  8 
At 8 weeks post-implantation, the animals were euthanized by CO2 asphyxiation and cervical 9 
dislocation. A 20 mm × 20 mm segment of calvarium containing the defect was resected using 10 
a dental saw and the explants retrieved were stored in 10% neutral buffered formalin for 4 days 11 
and then transferred to PBS prior to decalcification 12 
4.3.2. Microcomputed tomography 13 
The three dimensional (3D) structure of new bone produced within the cranial defect was 14 
analyzed using micro computed tomography (microCT). Scans were performed on a Scanco 15 
Medical 40 MicroCT system (Scanco Medical, Bassersdorf, Switzerland) with a 70 kVP Xray 16 
source and 112 µA (resolution of ~12µm). 3D reconstruction was performed using the standard 17 
Scanco software package and a threshold of 140 in a scale from 0 to 1000. Volume of interest 18 
(VOI) was defined to analyze a 6 mm defect region in order to assess healing in the center of 19 
the defect and to exclude any old bone at the defect edges. Repair was expressed as percentage 20 
bone within defect area.  21 
4.3.3 Histological analysis 22 
In addition to microCT, both qualitative and quantitative histological examinations were 23 
performed on explants in order to further assess the levels of bone formation. Explants were 24 
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first decalcified for a period of 5 weeks by immersing them in a solution of 1 
ethylenediaminetetraacetic acid (EDTA) 14% (w/v) at pH 7.4 with renewal of the solution 3–2 
4 times per week. Following decalcification, specimens were dehydrated in a graded series of 3 
ethanol solutions using an automated tissue processor, bisected and embedded in single paraffin 4 
wax blocks. Sections (7 µm thick) were cut from the mid-portion of each sample using a rotary 5 
microtome and mounted on poly-l-lysine slides. Qualitative and quantitative histological 6 
examinations were performed on explants in order to assess the levels of bone formation in the 7 
defect site. Each section was stained with Hematoxylin and Eosin (H&E). Hematoxylin stains 8 
cell nuclei purple, eosin stains extracellular matrix pink and bone appears dark pink/red. Images 9 
of each specimen were acquired and digitized using transmitted light and epifluorescence 10 
microscopic visualization (Nikon Microscope Eclipse 90i with NIS Elements software v3.06, 11 
Nikon Instruments Europe, The Netherlands). Quantitative analysis was performed on n=4 12 
sections from each specimen. Histomorphometrical analysis (blind) was carried out in order to 13 
quantify the healing response from the H&E-stained samples. The defect margin was identified 14 
and any new bone was quantified by measuring the area of bone nucleation sites (BNS) in each 15 
section and calculating the mean total area of these sites per group. The area of new bone 16 
formation was calculated using NIS Elements software v3.06 (Nikon Instruments Europe B.V, 17 
The Netherlands).  18 
4.4. Statistical analysis 19 
These data are represented as means ± standard error of the mean (SEM). Statistics were carried 20 
out using GraphPad Prism software using a general linear model ANOVA with Bonferroni 21 
post-test analysis performed for multiple comparisons. All experiments were performed with a 22 
sample size of 3 per treatment group unless otherwise stated. Statistical significance was taken 23 
at p<0.05 unless otherwise stated. 24 
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5. Results 1 
SEM analysis of the CHA scaffolds with and without rhBMP-2, shown in Figure 1A, 2 
demonstrated that the introduction of the growth factor did not lead to significant changes in 3 
the architectural properties of the scaffolds, which possess pore sizes of ca. 100 µm. 4 
Encouragingly, after a minor burst delivery in the first 4 h of the study, the growth factor is 5 
released from the scaffolds in a sustained manner, as observed in Figure 1B, suggesting a viable 6 
method of growth factor incorporation. After 21 days, approximately 25% (ca. 400ng) of the 7 
incorporated rhBMP-2 was released. 8 
9 
Figure 1. (A) SEM micrographs of collagen–hydroxyapatite scaffolds and collagen–10 
hydroxyapatite scaffolds incorporating rhBMP-2 (BMP-2/CHA). Images were taken at 200 × 11 
magnification and inset at 50 × magnification. (B) % cumulative and instant dose of RhBMP-12 
2 released from collagen–hydroxyapatite scaffolds. 13 
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Once it was established that the rhBMP-2 was delivered in a controlled fashion from the CHA 1 
scaffolds, we then investigated whether the protein was stable and bioactive specifically by 2 
testing whether it was capable of eliciting an osteoblastic response in terms of ALP activity 3 
and subsequent calcium deposition by preosteoblastic cells within non-loaded and rhBMP-2 4 
eluting scaffolds. Figure 2 summarizes the main findings of this study. As shown in Figure 2A, 5 
the cell number did not change after 3 days of culture on both scaffold types. However, 6 
although non-significant, there was a clear decrease in cell number when osteoblasts were 7 
cultured on GF eluting scaffolds for 7 days, compared to those grown on unloaded scaffolds 8 
indicative of reduced proliferation due to increased differentiation. The expression of ALP per 9 
DNA, depicted in Figure 2B, was enhanced on cells cultured on rhBMP-2 eluting scaffolds 10 
during the course of the study, with a significant increase observed after 7 days of culture. Most 11 
importantly from a therapeutic perspective, the amount of deposited calcium after 14 days of 12 
culture was significantly higher from cells grown on rhBMP-2 eluting scaffolds, as shown in 13 
Figure 2C; a cell-free CHA scaffold was utilized as a negative control. 14 
13 
 
 1 
Figure 2. (A) MC3T3 DNA content following 3 and 7 days of culture on collagen–2 
hydroxyapatite and rhBMP-2 eluting collagen–hydroxyapatite scaffolds. (B) MC3T3 ALP 3 
activity following 3 and 7 days of culture on the scaffolds (*p<0.05). (C) Cell mediated calcium 4 
deposition on collagen–hydroxyapatite and rhBMP-2 eluting collagen–hydroxyapatite 5 
scaffolds following 14 days of culture (*p<0.05). 6 
14 
 
Having confirmed the pro-osteogenic effect of the rhBMP-2 released from the CHA scaffolds 1 
and therefore the in vitro viability of the system developed to incorporate the protein, we then 2 
tested its ability to enhance bone regeneration in vivo using critically sized calvarial defects in 3 
male Wistar rats. Unloaded CHA scaffolds were also implanted as well as an untreated empty 4 
defect group. The results from the microCT analysis of the explanted defects 8 weeks post-5 
implantation are shown in Figure 3. The microCT images show that there was no de novo bone 6 
tissue within the defects that were untreated. Unloaded CHA scaffolds were able to elicit a 7 
certain level of tissue healing as demonstrated by new regions of bone within the defect. 8 
Importantly, the defect was completely filled with new bone in the animals where a BMP-2 9 
eluting scaffold was implanted; additionally, there were no signs of either bone anomalies or 10 
bone resorption on defect adjacent areas. Quantification of the newly formed bone within the 11 
defect confirmed these observations. It was evident that the new bone volume within the defects 12 
treated with GF-eluting CHA scaffolds was approximately 10 and 20 times higher than that of 13 
the unloaded CHA scaffold and empty defect respectively. 14 
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 1 
Figure 3. Representative microCT images of empty defect, collagen–hydroxyapatite and 2 
rhBMP-2 eluting collagen–hydroxyapatite scaffolds demonstrating the level of bone repair at 3 
8 weeks post-implantation. Quantitative microCT analysis demonstrating that the BMP-2/CHA 4 
group supported the highest level of bone formation compared to the empty defect and 5 
collagen–hydroxyapatite scaffold (***p<0.001).  6 
The histological examination of the explants after H&E staining, shown in Figure 4, confirms 7 
the results obtained by microCT. Only few, thin areas of new bone were observed in untreated 8 
defects or those treated with unloaded CHA scaffolds and scaffold resorption was evident 9 
(supplementary 1). In comparison the rhBMP-2 eluting scaffolds supported the formation of 10 
thick, mature, new bone within the defect site. Encouragingly, the appearance of the de novo 11 
bone tissue within these defects treated with rhBMP-2-loaded scaffolds was very similar to that 12 
of native bone. In all cases, the scaffolds had been completely resorbed 8 weeks after 13 
implantation and replaced with new bone, which completely bridged the defect sites. Similar 14 
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to microCT, there were no signs of bone anomalies or bone resorption around the defect site 1 
and the scaffolds were almost completely degraded and replaced with new bone.   2 
 3 
Figure 4. (A) Representative histological sections of the calvarium of an unoperated rat 4 
demonstrating the appearance of host bone. Representative histological section of explants 5 
from 7 mm calvarial defects in rats left empty (B), treated with collagen–hydroxyapatite 6 
scaffolds (C) or rhBMP-2 eluting collagen–hydroxyapatite scaffolds (D) following 8 weeks of 7 
implantation. Bone healing was considerably enhanced in defects where the rhBMP-2 eluting 8 
scaffold was implanted and defects were fully bridged following 8 weeks of implantation with 9 
an appearance similar to that of the unoperated control. 10 
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The quantitative analysis of the histomorphometrical analysis (Figure 5) corroborates the 1 
superior healing properties of BMP-2 eluting CHA scaffolds seen on micro CT analysis. At 8 2 
weeks post-implantation, the area of new bone in the defects treated with the GF eluting 3 
scaffolds was found to be circa 3 and 8 times higher than unloaded CHA and untreated empty 4 
defect controls respectively.  5 
 6 
Figure 5. Quantitative histomorphometric analysis indicating the mean total area of bone 7 
nucleation sites and accelerated bone healing in the rhBMP-2 eluting collagen–hydroxyapatite 8 
scaffold (BMP-2/CHA) compared to the empty defect and non-eluting collagen–9 
hydroxyapatite scaffold (***p<0.001). 10 
6. Discussion 11 
The present study aimed to develop a novel rhBMP-2 delivery system for the sustained release 12 
of low doses of rhBMP-2 incorporated directly within collagen–hydroxyapatite scaffolds 13 
without the use of carriers or pre/post fabrication functionalization processes. In order to 14 
accomplish this, rhBMP-2 was incorporated within the CHA scaffold during an intermediate 15 
fabrication step using a lyophilization process. The release profile of the growth factor from 16 
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these scaffolds and its bioactivity were evaluated in vitro, demonstrating the controlled delivery 1 
of bioactive growth factor for three weeks. Importantly, the superior healing properties of the 2 
rhBMP-2 eluting CHA scaffolds were also confirmed in vivo as shown by the outstanding 3 
regeneration of bone tissue within a rat calvarial defect 8 weeks post implantation. 4 
A biomimetic collagen-hydroxyapatite (CHA) porous scaffold for bone regeneration was 5 
chosen as an optimal matrix for the immobilization and controlled release of rhBMP-2. The 6 
CHA scaffold is a fully resorbable biomaterial and has been shown to be osteoconductive and 7 
osteoinductive in different animal models. Therefore, the sustained delivery of rhBMP-2 might 8 
enhance even further the regenerative capacity of the scaffold and thus its clinical application 9 
to new indications of use. Our goal was to facilitate the sustained delivery of the protein without 10 
the utilization of polymeric carriers or using chemical functionalization after scaffold 11 
fabrication processes, strategies approached previously by our group[17, 18]. The fabrication 12 
of the CHA scaffolds traditionally involves the blending of collagen and hydroxyapatite in an 13 
acidic suspension which is subsequently freeze-dried in order to produce a macroporous 14 
material. RhBMP-2 is stable at acidic pH such as that utilized in this suspension and, in 15 
addition, it has an affinity for HA crystals, a property that has motivated many researchers to 16 
fabricate calcium phosphate-based biomaterials as long-term delivery vehicles for rhBMP-17 
2[30-33]. In this regard, we utilized a similar approach by incorporating rhBMP-2 directly via 18 
an intermediate fabrication step into this suspension of collagen and hydroxyapatite, at a 19 
concentration that would elicit a pro-osteogenic response by MC3T3-E1 preosteoblastic cells 20 
upon release. 21 
One major advantage of the bioactive CHA scaffold developed in this study is that the amount 22 
of BMP-2 incorporated was 30 times lower (in µg/ cm2 of scaffold) than that present in the only 23 
currently approved material utilizing rhBMP-2 and the clinical gold standard for bone tissue 24 
regeneration in humans (INFUSE® bone graft) as well as being considerably lower than the 25 
19 
 
amount of rhBMP-7 used clinically (OP-1® bone graft)[34, 35]. RhBMP-2 was delivered in a 1 
sustained fashion for 21 days and, interestingly, there was only a minor burst release within the 2 
first 4 h, suggesting a strong interaction between the scaffold and the growth factor. According 3 
to previous studies, this interaction is based on water bridged hydrogen bonds between the -4 
OH, -NH2, and -COOH groups of the protein and the HA. Based on the different orientations 5 
of the protein, each of these groups might interact with the HA crystallites individually or 6 
multiple groups cooperatively[22, 23]. The strong bond between the growth factor and the HA 7 
component of the scaffold was further confirmed by the fact that only 25% of the incorporated 8 
rhBMP-2 had been released at the end of the study.  Theoretically, this scaffold also offers the 9 
potential for increased rhBMP-2 release due to substantive biodegradation typically seen 10 
following surgical implantation. The rhBMP-2 release profile, without a significant initial burst 11 
and showing sustained delivery of the protein, represents a significant advantage compared to 12 
the current commercial alternative, which has been linked to very severe secondary effects due 13 
to the untargeted and uncontrolled release of the growth factor. 14 
Having demonstrated that the rhBMP-2 was released in a controlled profile from the CHA 15 
scaffolds, we investigated whether these eluting bioactive scaffolds were capable of eliciting a 16 
pro-osteogenic response in vitro. With this purpose in mind, osteoblasts were seeded on 17 
rhBMP-2 eluting CHA scaffolds and their bioactivity was compared to that of cells grown on 18 
non-loaded scaffolds, used as control. The decrease in osteoblast cell number, together with 19 
the increase in ALP activity after 7 days of culture on rhBMP-2 eluting scaffolds compared to 20 
controls demonstrates that the delivered growth factor is promoting the differentiation of the 21 
cells towards an osteogenic lineage. This fact was further confirmed by the significant increase 22 
in calcium production from the osteoblasts cultured on rhBMP-2-loaded scaffolds compared to 23 
unloaded CHA scaffolds after 14 days of culture. These outcomes have been already observed 24 
by a number of studies utilizing rhBMP-2 on preosteoblasts[24, 36]. However, the fact that the 25 
20 
 
protein is capable of eliciting such a positive response following immobilization within the 1 
scaffolds without the use of carriers or functionalization is a significant finding. 2 
Based on these promising findings, the next step was to confirm the regenerative capacity of 3 
the delivery system in vivo. To this aim, rhBMP-2-loaded scaffolds were implanted within 4 
critical-sized defects in the calvariae of adult male Wistar rats. The characterization of the 5 
explanted defects 8 weeks post-implantation demonstrates the healing capacity of these 6 
scaffolds. The microCT images demonstrated that the bone defect was completely bridged with 7 
new bone when treated with rhBMP-2-loaded CHA scaffolds to a greater extent than previously 8 
seen with rhBMP-2 releasing materials in the same animal model[37, 38]. The 9 
histomorphometry analyses demonstrated evidence of scaffold resorption and a histological 10 
appearance similar to that of native bone when defects were treated with rhBMP-2-loaded CHA 11 
scaffolds. Importantly, there were no signs of bone anomalies or adjacent bone resorption on 12 
the analyzed explants; features that are indicative of an over dosage of rhBMP-2[39, 40]. These 13 
positive findings contradict some previous studies which suggested that rhBMP-2 should 14 
ideally be released within the defect area following a very specific release profile in vitro: a 15 
high burst followed by a sustained release of a much lower dose for achieving optimal bone 16 
healing[41]. 17 
The results shown in this work demonstrate that, following a relatively simple intermediate 18 
step introduced during the scaffold fabrication process, it is possible to obtain rhBMP-2 eluting 19 
CHA scaffolds with superior bone healing properties. These materials overcome the offsite 20 
release and non-controlled release of rhBMP-2, which are the main drawbacks of INFUSE®, 21 
the clinical gold standard for similar applications. In addition, the novelty of this work lies in 22 
the fact that the CHA matrix used as delivery platform for the long-term sustained delivery of 23 
BMP-2 is biomimetic, osteoinductive, osteoconductive and fully resorbable without the need 24 
for microparticle carriers or chemical functionalization. Furthermore, from a cost perspective, 25 
21 
 
the amount of rhBMP-2 utilized for achieving an optimal regenerative response is lower than 1 
that of the current commercial alternative. Thus, this study represents the first step on the 2 
development of a material with an immense clinical and commercial potential. In this sense, 3 
further studies are being carried out at the moment by our group, such as testing clinically 4 
acceptable sterilization techniques or evaluating the regenerative capacity of these materials on 5 
weight-wearing defects in conjunction with the INFUSE® delivery system at the same dose 6 
and in larger animal models. 7 
7. Conclusions 8 
Novel collagen–hydroxyapatite scaffolds releasing low doses of rhBMP-2 in a long-term, 9 
controlled fashion have been fabricated following a microparticle and chemical 10 
functionalization-free approach thus minimizing design complexity while overcoming the risks 11 
associated with high growth factor doses. The growth factor was incorporated into the scaffolds 12 
structure during their fabrication and, after release, elicited a pro-osteogenic response on 13 
preosteoblastic cells in vitro. These scaffolds induced the complete regeneration of a non-14 
healing critically sized calvarial defect in rats and were fully resorbed 8 weeks after 15 
implantation, demonstrating their superior healing properties in vivo.  16 
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Supplementary 2. Histological images of collagen-hydroxyapatite scaffolds at 4 and 8 2 
weeks post implantation in a rat calvarial defect model demonstrating that the scaffold is 3 
significantly resorbed following 8 weeks implantation. Yellow arrows represent areas of 4 
remaining scaffold, blue arrows represent bone nucleation sites/areas of new bone 5 
formation and host bone = hb. 6 
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